NCT00357032View on ClinicalTrials.gov

PXD101 in Treating Patients With Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2010

Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia
Interventions
DRUG

belinostat

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

91010

City of Hope, Duarte

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00357032 - PXD101 in Treating Patients With Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter